Experts are increasingly examining retatrutide, a novel drug from Eli Lilly, as a significant advance in physique loss . Different than many earlier approaches, retatrutide is a twin-action agonist targeting both GLP-1 and GIP, substances that impact appetite and glucose control . Early patient stu